ProtAffin wins orphan designation for anti-inflammatory drug

ProtAffin’s PA401 has been granted orphan medicinal product designation in the EU for the ‘prevention of delayed graft function after solid organ transplantation’.

PA401 is ProtAffin’s lead anti-inflammatory product and is a modified form of the human chemokine IL-8 which acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is often seen in the first days following solid organ transplantation.

Jason Slingsby, CEO of ProtAffin, said: “I am pleased that the European Medicines Evaluation Agency has approved the orphan medicinal product designation for PA401 for the prevention of delayed graft function after solid organ transplantation.”